Diagnostic Value of Circulating Free DNA for the Detection of EGFR Mutation Status in NSCLC: a Systematic Review and Meta-analysis

Overview

Journal Sci Rep

Specialty Science

Date 2014 Sep 10

PMID 25201768

Citations 109

Authors

Jie Luo

Li Shen

Di Zheng

Affiliations

Soon will be listed here.

Abstract

Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR mutation in tissues has obvious limitations. Circulating free DNA (cfDNA) has been reported as an alternative approach for the detection of EGFR mutations. This systematic review and meta-analysis was designed to assess the diagnostic performance of cfDNA, compared with tissues. True-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) values were extracted or calculated for each study. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated. A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall diagnostic performance. 20 eligible studies involving 2012 cases were included in this meta-analysis. The pooled sensitivity, specificity, PLR, NLR, and DOR were 0.674 (95%CI: 0.517-0.800), 0.935 (95%CI: 0.888-0.963), 10.307 (95%CI: 6.167-17.227), 0.348 (95%CI: 0.226-0.537), and 29.582 (95%CI: 4.582-60.012), respectively. The AUC was 0.93 (95% CI: 0.90-0.95). The meta-analysis suggests that detection of EGFR mutation by cfDNA is of adequate diagnostic accuracy and cfDNA analysis could be a promising screening test for NSCLC.

Citing Articles

Gynecologic Cancer Screening and Prevention: State of the Science and Practice.

Tran C, Diaz-Ayllon H, Abulez D, Chinta S, Williams-Brown M, Desravines N Curr Treat Options Oncol. 2025; .

PMID: 40014217 DOI: 10.1007/s11864-025-01301-z.

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era.

Costa J, Membrino A, Zanchetta C, Rizzato S, Cortiula F, Rossetto C Int J Mol Sci. 2025; 25(24.

PMID: 39769431 PMC: 11727717. DOI: 10.3390/ijms252413669.

Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment.

Ont Health Technol Assess Ser. 2024; 24(8):1-306.

PMID: 39698418 PMC: 11650780.

combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer.

Terada N, Koba H, Nanjo S, Kimura H, Nishiyama A, Yoneda T Transl Lung Cancer Res. 2024; 13(11):3067-3082.

PMID: 39670006 PMC: 11632430. DOI: 10.21037/tlcr-24-471.

Circulating tumor cells are associated with lung cancer subtypes: a large-scale retrospective study.

Zhu L, Gao E, Tomita Y, Li A, Tao B Transl Lung Cancer Res. 2024; 13(11):3122-3138.

PMID: 39670001 PMC: 11632433. DOI: 10.21037/tlcr-24-955.

References

Li L, Zhong W, Liao M, Chen L, Han B, Guan Z . [A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China]. Zhongguo Fei Ai Za Zhi. 2012; 15(6):332-9. PMC: 6000305. DOI: 10.3779/j.issn.1009-3419.2012.06.03. View

He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N . Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer. 2009; 125(10):2393-9. DOI: 10.1002/ijc.24653. View

Hirsch F, Varella-Garcia M, Bunn Jr P, Franklin W, Dziadziuszko R, Thatcher N . Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24(31):5034-42. DOI: 10.1200/JCO.2006.06.3958. View

Esposito A, Bardelli A, Criscitiello C, Colombo N, Gelao L, Fumagalli L . Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat Rev. 2013; 40(5):648-55. DOI: 10.1016/j.ctrv.2013.10.003. View

Giovannetti E, Zucali P, Peters G, Cortesi F, DIncecco A, Smit E . Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther. 2010; 9(3):581-93. DOI: 10.1158/1535-7163.MCT-09-0665. View

Brawley O, Kramer B . Cancer screening in theory and in practice. J Clin Oncol. 2005; 23(2):293-300. DOI: 10.1200/JCO.2005.06.107. View

Glas A, Lijmer J, Prins M, Bonsel G, Bossuyt P . The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 56(11):1129-35. DOI: 10.1016/s0895-4356(03)00177-x. View

Chen S, Chen Z, Guo A, Su J, Huang Y, Chen S . [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer tumor specimens from various ways by denaturing high-performance liquid chromatography]. Zhongguo Fei Ai Za Zhi. 2010; 13(9):850-5. PMC: 6000339. DOI: 10.3779/j.issn.1009-3419.2010.09.03. View

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I . Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97(5):339-46. DOI: 10.1093/jnci/dji055. View

10.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

11.

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

12.

Leeflang M, Deeks J, Gatsonis C, Bossuyt P . Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008; 149(12):889-97. PMC: 2956514. DOI: 10.7326/0003-4819-149-12-200812160-00008. View

13.

Huang Z, Wang Z, Bai H, Wu M, An T, Zhao J . The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thorac Cancer. 2017; 3(4):334-340. DOI: 10.1111/j.1759-7714.2012.00133.x. View

14.

Wang S, Han X, Hu X, Wang X, Zhao L, Tang L . Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta. 2014; 430:63-70. DOI: 10.1016/j.cca.2013.12.026. View

15.

Murtaza M, Dawson S, Tsui D, Gale D, Forshew T, Piskorz A . Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497(7447):108-12. DOI: 10.1038/nature12065. View

16.

Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A . Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10(8):472-84. DOI: 10.1038/nrclinonc.2013.110. View

17.

Bai H, Wang Z, Chen K, Zhao J, Lee J, Wang S . Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol. 2012; 30(25):3077-83. PMC: 5321076. DOI: 10.1200/JCO.2011.39.3744. View

18.

Bai H, Mao L, Wang H, Zhao J, Yang L, An T . Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 2009; 27(16):2653-9. DOI: 10.1200/JCO.2008.17.3930. View

19.

Diaz Jr L, Bardelli A . Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32(6):579-86. PMC: 4820760. DOI: 10.1200/JCO.2012.45.2011. View

20.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View